MODERATE IMPACT Ipsen will present 26 abstracts at TOXINS 2021. A key presentation titled AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations demonstrates long-duration of Dysport. Data from the long-term open-label extension study indicated that repeat cycles of Dysport resulted in at least 12 weeks duration for a large proportion of study patients for […]
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00clickgianthttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngclickgiant2021-01-15 21:01:052022-03-04 21:20:05TOXINS 2021: Ipsen to Present New Analysis of Phase 3 Data Demonstrating the long-duration of Dysport in Five Therapeutic Indications
November 19, 2020 Impact: High Results for Affimed’s AFM13 (CD30/CD16A ICE; Innate Cell Engager) in combination with Keytruda (pembrolizumab) in a phase 1b study for r/r Hodgkin Lymphoma patients have been published in the journal Blood. Key efficacy data included (n=30): ORR (Objective Response Rate): 88% (CR rate: 46%) at the recommended dose level Investigators deemed […]
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00clickgianthttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngclickgiant2020-12-03 18:26:502020-12-03 18:26:50Affimed’s AFM13 in Combination with Keytruda Demonstrates Promising Early Stage Results for Patients with r/r Hodgkin Lymphoma
November 10, 2020 Impact: Moderate Oramed is planning two new phase 2 studies to evaluate the efficacy and safety of its oral insulin candidate, ORMD-0801 in T2DM patients with NASH. The studies are due to start in November 2020. The first study is a double-blind study that will randomize 36 subjects in a 2:1 ratio to […]
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00clickgianthttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngclickgiant2020-11-23 15:16:512020-11-23 15:16:51Oramed Initiates Two Phase 2 Studies in T2D Patients with NASH
October 8, 2020 Impact: Moderate Krystal Biotech announced the presentation of preclinical data supporting the ongoing development of KB301. Data will be presented at the American Society for Dermatologic Surgery (ASDS) 2020 Virtual Meeting to be held October 9-11, 2020. KB301 is an investigational therapy designed to restore collagen homeostasis locally via directed expression of […]
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00clickgianthttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngclickgiant2020-10-15 18:35:022020-10-15 18:35:02Krystal Biotech Presents Positive Pre-Clinical Data of KB301 for Aesthetic Indications at ASDS 2020; Phase 1 Recruiting for KB301 Injections to Treat Deep Wrinkles and Acne Scars
September 15, 2020 Impact: Moderate At two recent investor conferences, Revance Therapeutics’ CEO, Mark Foley, provided updates on the company’s activities.
September 21, 2020 Impact: High inThought Research and Bloomberg Intelligence were joined by expert speakers in the field of Spinal Muscular Atrophy (SMA), Adrian Krainer, PhD, and Thomas Crawford, MD, to discuss the recent approval of the third disease-modifying therapy, Evrysdi. Key insights provided include: Patients currently stable with Zolgensma or Spinraza will likely not […]
TOXINS 2021: Ipsen to Present New Analysis of Phase 3 Data Demonstrating the long-duration of Dysport in Five Therapeutic Indications
MODERATE IMPACT Ipsen will present 26 abstracts at TOXINS 2021. A key presentation titled AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations demonstrates long-duration of Dysport. Data from the long-term open-label extension study indicated that repeat cycles of Dysport resulted in at least 12 weeks duration for a large proportion of study patients for […]
Affimed’s AFM13 in Combination with Keytruda Demonstrates Promising Early Stage Results for Patients with r/r Hodgkin Lymphoma
November 19, 2020 Impact: High Results for Affimed’s AFM13 (CD30/CD16A ICE; Innate Cell Engager) in combination with Keytruda (pembrolizumab) in a phase 1b study for r/r Hodgkin Lymphoma patients have been published in the journal Blood. Key efficacy data included (n=30): ORR (Objective Response Rate): 88% (CR rate: 46%) at the recommended dose level Investigators deemed […]
Oramed Initiates Two Phase 2 Studies in T2D Patients with NASH
November 10, 2020 Impact: Moderate Oramed is planning two new phase 2 studies to evaluate the efficacy and safety of its oral insulin candidate, ORMD-0801 in T2DM patients with NASH. The studies are due to start in November 2020. The first study is a double-blind study that will randomize 36 subjects in a 2:1 ratio to […]
Krystal Biotech Presents Positive Pre-Clinical Data of KB301 for Aesthetic Indications at ASDS 2020; Phase 1 Recruiting for KB301 Injections to Treat Deep Wrinkles and Acne Scars
October 8, 2020 Impact: Moderate Krystal Biotech announced the presentation of preclinical data supporting the ongoing development of KB301. Data will be presented at the American Society for Dermatologic Surgery (ASDS) 2020 Virtual Meeting to be held October 9-11, 2020. KB301 is an investigational therapy designed to restore collagen homeostasis locally via directed expression of […]
Revance Update: Significant 2020 Catalysts Remain
September 15, 2020 Impact: Moderate At two recent investor conferences, Revance Therapeutics’ CEO, Mark Foley, provided updates on the company’s activities.
Assessing the Evolving Spinal Muscular Atrophy (SMA) Landscape
September 21, 2020 Impact: High inThought Research and Bloomberg Intelligence were joined by expert speakers in the field of Spinal Muscular Atrophy (SMA), Adrian Krainer, PhD, and Thomas Crawford, MD, to discuss the recent approval of the third disease-modifying therapy, Evrysdi. Key insights provided include: Patients currently stable with Zolgensma or Spinraza will likely not […]